We hypothesized that the abuse potential of certain types of inhalants could be evaluated in animals by determining the overlap in their profile of behavioral effects with that of CNS depressant drugs and other depressant-like abused inhalants. For our first attempt in evaluating a solvent with an unknown abuse potential we tested ISOPAR-E(TM). ISOPAR-E(TM) is a mixture of predominately C8-C9 isoparaffinic hydrocarbons that is being used more and more frequently as a solvent in industrial and consumer products, including, but not limited to, typewriter correction fluids. Presently, nothing is known about the potential for abuse of products containing this solvent. In the present studies, we compared the volatility of ISOPAR-E(TM) and the abused solvent 1,1,1-trichloroethane (TCE) in our exposure systems. Additionally, five behavioral procedures were conducted in mice to compare the effects of the two compounds. The results demonstrate that: (1) ISOPAR-E(TM) was less volatile than TCE; (2) ISOPAR-E(TM) produced a somewhat different profile of effects than did TCE as assessed with a functional observational battery; (3) unlike TCE, ISOPAR-E(TM) did not affect performance on tests of motor coordination; (4) TCE and ISOPAR-E(TM) produced concentration-related decreases in schedule-controlled operant performance with recovery from TCE being somewhat more rapid. (5) ISOPAR-E(TM) produced cross dependence in TCE-dependent mice; and (6) both TCE and ISOPAR-E(TM) produced substantial levels of ethanol-lever responding in a drug discrimination procedure, although the ethanol-like effects of ISOPAR-E(TM) only occurred at response rate decreasing concentrations. Overall, there was a poorer separation of behavioral and lethal concentrations for ISOPAR-E(TM) than for TCE. Although a somewhat different profile of behavioral effects was obtained with ISOPAR-E(TM) and TCE, we cannot say with certainty if enough similarities exist with abused inhalants to predict that ISOPAR-E(TM) would be subject to depressant-like abuse. Nonetheless, the feasibility of preclinical assessment of abuse potential of inhalants was demonstrated. (C) 1997 Elsevier Science Ireland Ltd.
